Asia-Pacific hepatitis C market to surpass $8.3 billion by 2023, says new report

The hepatitis C market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $5.3 billion in 2016 to $8.3 billion by 2023, at a compound annual growth rate of 6.4%.

According to business intelligence provider GBI Research’s latest report: ‘Hepatitis C Therapeutics in Asia-Pacific Markets to 2023,’ this growth will primarily be driven by the arrival of investigational pipeline treatments (most notably a set of pan-genotypic DAAs), the expansion of treatment coverage to patients who previously did not qualify for DAA treatment, further elimination of ribavirin and interferon based treatment algorithms, and the market penetration of DAAs in China.

However, the impact of high SVR rates obtained by newer DAAs is likely to heavily reduce the prevalence pool and thus will limit market size growth rates. Driven by these factors, the Australian and South Korean hepatitis C markets will decline by the end of forecast period, while China, Japan and India will see an increase in market size.